23–27 October 2026 | IFEMA MADRID in Madrid, Spain
Making sense of oncology at ESMO
The ESMO Congress is one of the most influential meetings in global oncology, bringing together more than 30,000 oncology professionals to share late-breaking research, practice-changing clinical data and the latest advances across the cancer care landscape. For biopharma teams, ESMO is a pivotal moment to understand how emerging evidence is reshaping treatment paradigms, competitive dynamics and future opportunities.
At this year’s congress, Prescient is looking forward to engaging with the latest clinical data, evolving scientific narratives and shifts across the oncology landscape.
With thousands of abstracts, presentations and discussions taking place throughout the meeting, the challenge is not simply accessing information, but understanding what matters most and translating it into strategic action. We work with oncology teams to interpret the evidence, assess the implications and identify clear next steps.
Focus at ESMO 2026
During ESMO, our team will be following key developments across the oncology landscape, including late-breaking clinical data, evolving treatment paradigms and emerging areas of scientific and commercial importance. We will be assessing how these developments may influence the competitive environment and what they could mean for future clinical, development and commercial decision-making.
Our oncology experience
Prescient has supported oncology teams across a wide range of strategic and evidence-based challenges, from early development through to commercialization.
- 1,500+ oncology projects delivered over 10+ years
- 250+ assets and indications supported
- Average of 7 years supporting an oncology asset
- Experience across solid tumours, haematological malignancies, rare cancers and major therapeutic modalities
Our work spans scientific insight, strategy, and stakeholder perspectives, helping teams navigate complexity at each stage of the asset lifecycle.
Meet us at ESMO
Our team will be on-site throughout ESMO Congress 2026, bringing deep expertise across oncology strategy, evidence generation and commercial decision-making. We’d welcome the opportunity to discuss the latest data emerging from the congress and explore what it could mean for your assets, portfolio or strategic priorities.
Book a meeting with the Prescient team by completing the form below.
From ASCO 2026 to ESMO 2026
